AssetMark Inc
KRYS icon

AssetMark Inc’s Krystal Biotech KRYS Stock Holding History

AssetMark Inc’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Buy
3,739
+582
+18% +$174K ﹤0.01% 1027
2026
Q1 		$816K Buy
+3,157
New +$840K ﹤0.01% 1077
2025
Q1 		– Sell
-1
Closed -$157 – 2697
2024
Q4 		$157 Buy
+1
New +$177 ﹤0.01% 2500

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AssetMark Inc's KRYS Position: Q2 2026 in Review

AssetMark Inc increased its Krystal Biotech (KRYS) stake by 18% in Q2 2026, buying an estimated $174K and bringing the position to 3,739 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

AssetMark Inc first reported a position in KRYS in Q4 2024 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • AssetMark Inc held 3,739 shares of Krystal Biotech worth $1.39M as of Q2 2026.
  • AssetMark Inc bought 582 Krystal Biotech shares in Q2 2026, an estimated $174K.
  • Krystal Biotech made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1027 holding.
  • AssetMark Inc first reported a position in Krystal Biotech in Q4 2024 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.